Completion of hepatitis C virus replication cycle in heterokaryons excludes dominant restrictions in human non-liver and mouse liver cell lines

PLoS Pathogens

Volumn 7, Issue 4, 2011, Pages

  Frentzen, Anne ^a   Hüging, Kathrin ^a   Bitzegeio, Julia ^a   Friesland, Martina ^a   Haid, Sibylle ^a   Gentzsch, Juliane ^a   Hoffmann, Markus ^b   Lindemann, Dirk ^c   Zimmer, Gert ^d   Zielecki, Florian ^e   Weber, Friedemann ^e   Steinmann, Eike ^a   Pietschmann, Thomas ^a  

^a INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^b UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (Switzerland)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; ALPHA INTERFERON;

ANIMAL CELL; ANIMAL CELL CULTURE; ANTIGEN DETECTION; ARTICLE; CONTROLLED STUDY; HEPATITIS C VIRUS; HETEROKARYON; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MOUSE; NONHUMAN; VIRAL TROPISM; VIRUS EXPRESSION; VIRUS INHIBITION; VIRUS REPLICATION; ANIMAL; ANIMAL MODEL; CELL FUSION; CELL LINE; CELL STRAIN HEK293; GENETIC TRANSFECTION; GENETICS; HELA CELL; PHYSIOLOGY;

ANIMALIA; HEPATITIS C VIRUS; PAN;

ANIMALS; CELL FUSION; CELL LINE; HEK293 CELLS; HELA CELLS; HEPACIVIRUS; HUMANS; INTERFERON-ALPHA; MICE; MODELS, ANIMAL; TRANSFECTION; VIRUS REPLICATION;

EID: 79955752803     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002029     Document Type: Article

References (73)

1. Alter MJ, (2007) Epidemiology of hepatitis C virus infection. World J Gastroenterol 13: 2436-2441.
2. Bartenschlager R, Frese M, Pietschmann T, (2004) Novel insights into hepatitis C virus replication and persistence. Adv Virus Res 63: 71-180.
3. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, et al. (2005) Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42: 962-973.
4. Hoofnagle JH, (1997) Hepatitis C: the clinical spectrum of disease. Hepatology 26: 15S-20S.
5. Manns MP, Wedemeyer H, Cornberg M, (2006) Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55: 1350-1359.
6. Bukh J, (2004) A critical role for the chimpanzee model in the study of hepatitis C. Hepatology 39: 1469-1475.
7. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, et al. (2001) Hepatitis C virus replication in mice with chimeric human livers. Nat Med 7: 927-933.
8. Meuleman P, Leroux-Roels G, (2008) The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV. Antiviral Res 80: 231-238.
9. Ploss A, Rice CM, (2009) Towards a small animal model for hepatitis C. EMBO Rep 10: 1220-1227.
10. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, et al. (2009) Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457: 882-886.
11. Flint M, von Hahn T, Zhang J, Farquhar M, Jones CT, et al. (2006) Diverse CD81 proteins support hepatitis C virus infection. J Virol 80: 11331-11342.
12. Catanese MT, Ansuini H, Graziani R, Huby T, Moreau M, et al. (2010) Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol 84: 34-43.
13. Haid S, Windisch MP, Bartenschlager R, Pietschmann T, (2010) Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line. J Virol 84: 964-975.
14. Bitzegeio J, Bankwitz D, Hueging K, Haid S, Brohm C, et al. (2010) Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. PLoS Pathog 6: e1000978.
15. Zhu Q, Guo JT, Seeger C, (2003) Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells. J Virol 77: 9204-9210.
16. Kato T, Date T, Miyamoto M, Zhao Z, Mizokami M, et al. (2005) Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon. J Virol 79: 592-596.
17. Ali S, Pellerin C, Lamarre D, Kukolj G, (2004) Hepatitis C virus subgenomic replicons in the human embryonic kidney 293 cell line. J Virol 78: 491-501.
18. Date T, Kato T, Miyamoto M, Zhao Z, Yasui K, et al. (2004) Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells. J Biol Chem 279: 22371-22376.
19. Chang KS, Cai Z, Zhang C, Sen GC, Williams BR, et al. (2006) Replication of hepatitis C virus (HCV) RNA in mouse embryonic fibroblasts: protein kinase R (PKR)-dependent and PKR-independent mechanisms for controlling HCV RNA replication and mediating interferon activities. J Virol 80: 7364-7374.
20. Uprichard SL, Chung J, Chisari FV, Wakita T, (2006) Replication of a hepatitis C virus replicon clone in mouse cells. Virol J 3: 89.
21. Strebel K, Luban J, Jeang KT, (2009) Human cellular restriction factors that target HIV-1 replication. BMC Med 7: 48.
22. Goff SP, (2004) Retrovirus restriction factors. Mol Cell 16: 849-859.
23. Sheehy AM, Gaddis NC, Choi JD, Malim MH, (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650.
24. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, et al. (2004) The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427: 848-853.
25. Neil SJ, Zang T, Bieniasz PD, (2008) Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451: 425-430.
26. Rocha-Perugini V, Montpellier C, Delgrange D, Wychowski C, Helle F, et al. (2008) The CD81 partner EWI-2wint inhibits hepatitis C virus entry. PLoS One 3: e1866.
27. Kukihara H, Moriishi K, Taguwa S, Tani H, Abe T, et al. (2009) Human VAP-C negatively regulates hepatitis C virus propagation. J Virol 83: 7959-7969.
28. Koutsoudakis G, Kaul A, Steinmann E, Kallis S, Lohmann V, et al. (2006) Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol 80: 5308-5320.
29. Blight KJ, McKeating JA, Rice CM, (2002) Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 76: 13001-13014.
30. Windisch MP, Frese M, Kaul A, Trippler M, Lohmann V, et al. (2005) Dissecting the interferon-induced inhibition of hepatitis C virus replication by using a novel host cell line. J Virol 79: 13778-13793.
31. Steinmann E, Brohm C, Kallis S, Bartenschlager R, Pietschmann T, (2008) Efficient trans-encapsidation of hepatitis C virus RNAs into infectious virus-like particles. J Virol 82: 7034-7046.
32. Blakqori G, Delhaye S, Habjan M, Blair CD, Sanchez-Vargas I, et al. (2007) La Crosse bunyavirus nonstructural protein NSs serves to suppress the type I interferon system of mammalian hosts. J Virol 81: 4991-4999.
33. Sumpter R Jr, Loo YM, Foy E, Li K, Yoneyama M, et al. (2005) Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 79: 2689-2699.
34. Witteveldt J, Evans MJ, Bitzegeio J, Koutsoudakis G, Owsianka AM, et al. (2009) CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol 90: 48-58.
35. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, et al. (2007) Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446: 801-805.
36. Skelley AM, Kirak O, Suh H, Jaenisch R, Voldman J, (2009) Microfluidic control of cell pairing and fusion. Nat Methods 6: 147-152.
37. Lindemann D, Goepfert PA, (2003) The foamy virus envelope glycoproteins. Curr Top Microbiol Immunol 277: 111-129.
38. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, et al. (2006) Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 103: 7408-7413.
39. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P, (2005) Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309: 1577-1581.
40. Chang J, Guo JT, Jiang D, Guo H, Taylor JM, et al. (2008) Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J Virol 82: 8215-8223.
41. Lin LT, Noyce RS, Pham TN, Wilson JA, Sisson GR, et al. (2010) Replication of subgenomic hepatitis C virus replicons in mouse fibroblasts is facilitated by deletion of interferon regulatory factor 3 and expression of liver-specific microRNA 122. J Virol 84: 9170-9180.
42. Friew YN, Boyko V, Hu WS, Pathak VK, (2009) Intracellular interactions between APOBEC3G, RNA, and HIV-1 Gag: APOBEC3G multimerization is dependent on its association with RNA. Retrovirology 6: 56.
43. Varthakavi V, Smith RM, Bour SP, Strebel K, Spearman P, (2003) Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc Natl Acad Sci U S A 100: 15154-15159.
44. Yu X, Yu Y, Liu B, Luo K, Kong W, et al. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302: 1056-1060.
45. Goffinet C, Allespach I, Homann S, Tervo HM, Habermann A, et al. (2009) HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 5: 285-297.
46. McNatt MW, Zang T, Hatziioannou T, Bartlett M, Fofana IB, et al. (2009) Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog 5: e1000300.
47. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, et al. (2003) Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114: 21-31.
48. Bishop KN, Holmes RK, Sheehy AM, Malim MH, (2004) APOBEC-mediated editing of viral RNA. Science 305: 645.
49. Kirchhoff F, (2010) Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe 8: 55-67.
50. Turelli P, Mangeat B, Jost S, Vianin S, Trono D, (2004) Inhibition of hepatitis B virus replication by APOBEC3G. Science 303: 1829.
51. Jouvenet N, Neil SJ, Zhadina M, Zang T, Kratovac Z, et al. (2009) Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol 83: 1837-1844.
52. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P, (2009) Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci U S A 106: 2886-2891.
53. Sakuma T, Noda T, Urata S, Kawaoka Y, Yasuda J, (2009) Inhibition of Lassa and Marburg virus production by tetherin. J Virol 83: 2382-2385.
54. Pardieu C, Vigan R, Wilson SJ, Calvi A, Zang T, et al. (2010) The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. PLoS Pathog 6: e1000843.
55. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, et al. (2005) Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437: 1167-1172.
56. Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale M Jr, (2008) Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 454: 523-527.
57. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, et al. (2005) Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 102: 2992-2997.
58. Ahlen G, Derk E, Weiland M, Jiao J, Rahbin N, et al. (2009) Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes. Gut 58: 560-569.
59. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, et al. (2005) Complete replication of hepatitis C virus in cell culture. Science 309: 623-626.
60. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, et al. (2005) Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 102: 9294-9299.
61. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11: 791-796.
62. Burgel B, Friesland M, Koch A, Manns MP, Wedemeyer H, et al. (2010) Hepatitis C virus enters human peripheral neuroblastoma cells- evidence for extra-hepatic cells sustaining hepatitis C virus penetration. J Viral Hepat doi:10.1111/j.1365-2893.2010.01339.x.
63. Lindemann D, Pietschmann T, Picard-Maureau M, Berg A, Heinkelein M, et al. (2001) A particle-associated glycoprotein signal peptide essential for virus maturation and infectivity. J Virol 75: 5762-5771.
64. Hanika A, Larisch B, Steinmann E, Schwegmann-Wessels C, Herrler G, et al. (2005) Use of influenza C virus glycoprotein HEF for generation of vesicular stomatitis virus pseudotypes. J Gen Virol 86: 1455-1465.
65. Sahai A, Malladi P, Melin-Aldana H, Green RM, Whitington PF, (2004) Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am J Physiol Gastrointest Liver Physiol 287: G264-273.
66. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, et al. (1998) A third-generation lentivirus vector with a conditional packaging system. J Virol 72: 8463-8471.
67. Kalajzic I, Stover ML, Liu P, Kalajzic Z, Rowe DW, et al. (2001) Use of VSV-G pseudotyped retroviral vectors to target murine osteoprogenitor cells. Virology 284: 37-45.
68. Spearman C, (1908) The method of "right and wrong cases" ("constant stimuli") without Gauss's formulae. British Journal of Psychology 2: 227-242.
69. Kärber G, (1931) Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Archiv für experimentelle Pathologie und Pharmakologie 162: 480-487.
70. Keck ZY, Li SH, Xia J, von Hahn T, Balfe P, et al. (2009) Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. J Virol 83: 6149-6160.
71. Owsianka A, Clayton RF, Loomis-Price LD, McKeating JA, Patel AH, (2001) Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J Gen Virol 82: 1877-1883.
72. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
73. Jorns C, Holzinger D, Thimme R, Spangenberg HC, Weidmann M, et al. (2006) Rapid and simple detection of IFN-neutralizing antibodies in chronic hepatitis C non-responsive to IFN-alpha. J Med Virol 78: 74-82.